keyword
MENU ▼
Read by QxMD icon Read
search

Interferon-beta

keyword
https://www.readbyqxmd.com/read/29674057/high-resolution-glycoform-profiling-of-intact-therapeutic-proteins-by-hydrophilic-interaction-chromatography-mass-spectrometry
#1
Elena Domínguez-Vega, Sara Tengattini, Claudia Peintner, Jordy van Angeren, Caterina Temporini, Rob Haselberg, Gabriella Massolini, Govert W Somsen
Glycosylation is considered a critical quality attribute of therapeutic proteins. Protein heterogeneity introduced by glycosylation includes differences in the nature, number and position of the glycans. Whereas analysis of released glycans and glycopeptides provides information about the composition and/or position of the glycan, intact glycoprotein analysis allows assignment of individual proteoforms and co-occurring modifications. Yet, resolving protein glycoforms at the intact level is challenging. We have explored the capacity of hydrophilic liquid chromatography-mass spectrometry (HILIC-MS) for assessing glycosylation patterns of intact pharmaceutical proteins by analyzing the complex glycoproteins interferon-beta-1a (rhIFN-β - 1a) and recombinant human erythropoietin (rhEPO)...
July 1, 2018: Talanta
https://www.readbyqxmd.com/read/29671656/interferon-beta-injection-site-reactions-in-patients-with-multiple-sclerosis
#2
Martina Maurelli, Roberto Bergamaschi, Ambra Antonini, Maria Concetta Fargnoli, Elisa Puma, Giulia Mallucci, Rocco Totaro, Giampiero Girolomoni
Interferon-beta (IFNβ) are effective treatments for relapsing multiple sclerosis. IFNβ treatment includes subcutaneous (sc) IFNβ-1b, intramuscular and sc IFNβ-1a, and sc pegylated IFNβ-1a (PEG-IFNβ-1a). PEG-IFNβ-1a offers the advantage of a prolonged duration of action with a less frequent administration (every 2 weeks) and a higher patient adherence. However, the use of subcutaneous interferons could be characterized by potential skin toxicity. Injection site reactions (ISRs), featured by erythema, edema, pain and pruritus, are the most common adverse reactions...
April 19, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29667554/establishment-of-novel-reporter-cells-stably-maintaining-transcription-factor-driven-human-secreted-alkaline-phosphatase-expression
#3
Riho Kurata, Asuka Kumagai, Xiaofeng Cui, Masamitsu Harada, Jun Nagai, Yasuhiro Yoshida, Kei-Ichi Ozaki, Yoshimasa Tanaka, Tomo Yonezawa
BACKGROUND: Transcriptional regulation is very important and pivotal function in myriad biological responses. Thus, methods to determine transcriptional activity are required in not only basic medical research but also drug discovery. We established novel reporter constructs using human secreted embryonic alkaline phosphatase (SEAP) and Epstein-Barr virus nuclear antigen (EBNA) 1, which can maintain constructs synchronized to host cell replication. METHODS: We established nuclear factor-kappa B (NFkB) or interferon regulatory factor (IRF) driven SEAP expression constructs and then, introduced them into culture cells...
April 17, 2018: Current Pharmaceutical Biotechnology
https://www.readbyqxmd.com/read/29663814/new-biological-agents-in-the-treatment-of-multiple-sclerosis
#4
M Buc
Multiple sclerosis (MS) is an inflammatory disease induced by autoimmune processes. Their understanding has resulted in an introduction of biological agents to its treatment. Interferon beta and glatiramer acetate have been in clinical practice for more than 20 years. Nowadays, novel biologics, which target molecules involved in immunopathological processes more specifically have entered the scene. They are represented by monoclonal antibodies binding to molecules VLA4 (natalizumab), CD20 (ocrelizumab), CD52 (alemtuzumab) or alpha subunit of IL-2 receptor (daclizumab) or by small molecules such as those modulating the receptors involved in regulation of lymphocyte migration (fingolimod, ozanimod) or in induction of lymphopenia by apoptosis (dimethyl fumarate, cladribine)...
2018: Bratislavské Lekárske Listy
https://www.readbyqxmd.com/read/29660869/dysregulation-of-major-functional-genes-in-frontal-cortex-by-maternal-exposure-to-carbon-black-nanoparticle-is-not-ameliorated-by-ascorbic-acid-pretreatment
#5
Atsuto Onoda, Ken Takeda, Masakazu Umezawa
Recent cohort studies have revealed that perinatal exposure to particulate air pollution, including carbon-based nanoparticles, increases the risk of brain disorders. Although developmental neurotoxicity is currently a major issue in the toxicology of nanoparticles, critical information for understanding the mechanisms underlying the developmental neurotoxicity of airway exposure to carbon black nanoparticle (CB-NP) is still lacking. In order to investigate these mechanisms, we comprehensively analyzed fluctuations in the gene expression profile of the frontal cortex of offspring mice exposed maternally to CB-NP, using microarray analysis combined with Gene Ontology information...
April 11, 2018: Science of the Total Environment
https://www.readbyqxmd.com/read/29652301/-the-results-of-an-open-comparative-retrospective-trial-of-the-course-of-multiple-sclerosis-during-treatment-with-infibeta-and-other-interferon-beta-bioanalogues-and-glatiramer-acetate
#6
F A Khabirov, T I Khaybullin, E V Granatov, S R Shakirzianova, N N Babicheva, O S Kochergina, E F Rakhmatullina, G M Akhmedova, L A Averyanova, M A Yakupov, Zh F Sabirov
AIM: To evaluate the efficacy and safety of the interferon beta-1b bioanalogue 'infibeta' in the treatment of multiple sclerosis (MS) in comparison with other interferon beta bioanalogues and the generic drug glatiramer acetate. MATERIAL AND METHODS: The data of 500 patients with MS treated with different disease-modifying drugs were analyzed. Patients of group 1 (n=95) received infibeta; group 2 (n=108) interferon beta-1b; group 3 (n=83) genfaxon-44; group 4 (n=109) sinnovex; group 5 (n=105) aksoglatiran FS...
2018: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/29645071/daclizumab-in-multiple-sclerosis
#7
REVIEW
F C Perez-Miralles
INTRODUCTION: Daclizumab is a monoclonal antibody directed against the CD25 subunit of the interleukin-2 receptor, investigated as a disease-modifying therapy in relapsing-remitting multiple sclerosis. The present review addresses how the drug was developed, the known mechanism of action of the drug and the up-to-date data of efficacy and safety. DEVELOPMENT: Daclizumab has shown superiority in prevention of relapses against placebo and low-dose interferon beta-1a at a level that puts it on par with the rest of current first-line drugs...
April 16, 2018: Revista de Neurologia
https://www.readbyqxmd.com/read/29607711/pediatric-multiple-sclerosis-in-the-united-arab-emirates-characteristics-from-a-multicenter-study-and-global-comparison
#8
Fatima Y Ismail, Eliza Gordon-Lipkin, Katherine Huether, Iain Blair, Miklós Szólics, Taoufik Alsaadi, Faisal Aziz, Jehan Suleiman, Nicoline Schiess
We delineate the clinical characteristics, incidence, and prevalence of pediatric-onset multiple sclerosis in Abu Dhabi, United Arab Emirates, from 2010 to 2014. Eighty-two patients (65% female) were identified. Fifty-three (64.6%) were Emiratis (45 from Abu Dhabi and 8 from 5 other emirates) and 29 were expatriates. Mean age of onset was 15.9 years overall, 15.3 years in males and 16.3 years in females. Patients with onset before age 12 years presented with visual symptoms while those with onset after age 12 years presented with a mixture of visual, motor and sensory symptoms...
January 1, 2018: Journal of Child Neurology
https://www.readbyqxmd.com/read/29590134/patient-preferences-for-interferon-beta-in-iran-a-discrete-choice-experiment
#9
Farimah Rahimi, Hamid Reza Rasekh, Ezatollah Abbasian, Farzad Peiravian, Masoud Etemadifar, Fereshteh Ashtari, Ali Mohammad Sabzghabaee, Mohammad Reza Amirsadri
Multiple sclerosis is a chronic, progressive, and common disease affecting the central nervous system in young adults. Interferon-beta is one of the most widely used medicines to reduce the disease progression. Given the variety of drugs in this category, we aimed to identify the preferences of patients for IFN-β that play an important role in policymaking in this area. Discrete choice experiment method was used in the present study to identify and prioritize those attributes that are of interest to MS patients and increases the utility of the use of IFN-β in their treatment...
2018: PloS One
https://www.readbyqxmd.com/read/29589548/characterization-of-regulatory-t-cells-in-multiple-sclerosis-patients-treated-with-interferon-beta-1a
#10
Mohsen Ebrahimi, Ali Ganji, Sarah Zahedi, Parisa Nourbakhsh, Keyvan Ghasami, Ghasem Mosayebi
BACKGROUND: Regulatory T-Cells (Treg Cells), as one of the immune system components, have been highly effective in the autoimmune diseases prevention, particularly multiple sclerosis (MS). Cytokine-based therapies such as interferon beta-1a (IFN-β1a) is a common drug in MS treatment; however, its exact mechanisms are insufficiently described. OBJECTIVE: Therefore, the goal of this study was to evaluate the in vivo impact of IFN-β1a on the Treg Cells in MS. METHODS: In this case-control study, Treg Cells were analysed by flowcytometry in IFN-β1a-treated relapsing-remitting MS (RRMS) in comparison with new cases of MS and healthy subjects...
March 27, 2018: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/29581840/interferon-beta-induces-apoptosis-in-nasopharyngeal-carcinoma-cells-via-the-trail-signaling-pathway
#11
Anna Makowska, Lora Wahab, Till Braunschweig, Nikiforos-Ioannis Kapetanakis, Christian Vokuhl, Bernd Denecke, Lian Shen, Pierre Busson, Udo Kontny
The combination of neoadjuvant chemotherapy, radiochemotherapy, and maintenance therapy with interferon beta (IFNβ) has led to superior results in the treatment of children and adolescents with nasopharyngeal carcinoma (NPC). However, nothing is known about the mechanism of the antitumor activity of IFNβ in NPC. Here, we investigate the role of IFNβ on apoptosis in NPC cells. Six NPC cell lines, one patient-derived NPC xenograft (PDX) and one SV40-transformed nasoepithelial cell line were used. Induction of apoptosis by IFNβ was measured by flow cytometric analysis of subG1-DNA-content, Hoechst 33258 staining and activation of caspase-3...
March 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/29568544/no-evidence-of-disease-activity-neda-analysis-by-epochs-in-patients-with-relapsing-multiple-sclerosis-treated-with-ocrelizumab-vs-interferon-beta-1a
#12
Eva Havrdová, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Fred Lublin, Krzysztof Selmaj, Anthony Traboulsee, Shibeshih Belachew, Iain Bennett, Regine Buffels, Hideki Garren, Jian Han, Laura Julian, Julie Napieralski, Stephen L Hauser, Gavin Giovannoni
Background: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS). Objective: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status. Methods: NEDA was assessed in a modified intent-to-treat population ( n  = 1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN β-1a; 44 μg)...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29565165/effect-of-fish-and-olive-oil-on-mitochondrial-atpase-activity-and-membrane-fluidity-in-patients-with-relapsing-remitting-multiple-sclerosis-treated-with-interferon-beta-1-b
#13
Erandis D Torres-Sánchez, Fermín P Pacheco-Moisés, Miguel A Macias-Islas, Eddic W Morales-Sánchez, Viridiana Ramírez-Ramírez, Alfredo J Celis de la Rosa, Margarita Cid-Hernández, Tanya E Sorto-Gómez, Genaro G Ortiz
BACKGROUND: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system associated with increased oxidative stress (OS) and mitochondrial alterations. Fish oil consumption has neuroprotective, antioxidant and anti-inflammatory effects in patients with relapsing-recurrent MS (RR-MS). OBJECTIVE: To evaluate changes in the hydrolytic activity of ATP synthase and mitochondrial membrane fluidity in patients with RR-MS who receive fish oil or olive oil as a dietary supplement...
January 12, 2018: Nutrición Hospitalaria: Organo Oficial de la Sociedad Española de Nutrición Parenteral y Enteral
https://www.readbyqxmd.com/read/29559569/interleukin-1%C3%AE-signaling-in-dendritic-cells-induces-antiviral-interferon-responses
#14
Lauren D Aarreberg, Courtney Wilkins, Hilario J Ramos, Richard Green, Michael A Davis, Kwan Chow, Michael Gale
Induction of interferon beta (IFN-β), IFN-stimulated genes (ISGs), and inflammatory responses is critical for control of viral infection. We recently identified an essential linkage of stimulation of the inflammatory cytokine interleukin-1β (IL-1β) and induction of ISGs that function as host restriction pathways against the emerging flavivirus West Nile virus (WNV) in vivo Here we utilized ex vivo global transcriptome analysis of primary dendritic cells, known targets of WNV replication, to define gene signatures required for this IL-1β-driven antiviral response...
March 20, 2018: MBio
https://www.readbyqxmd.com/read/29526318/a-comparative-study-of-melatonin-and-immunomodulatory-therapy-with-interferon-beta-and-glatiramer-acetate-in-a-mouse-model-of-multiple-sclerosis
#15
E J Ramos González, L J Ramirez Jirano, D Z García Martínez, G G Ortiz, L F Jave Suárez, C A Leal Cortes, O K Bitzer Quintero
INTRODUCTION: Multiple sclerosis (MS) is a chronic, demyelinating, autoimmune disease of the central nervous system causing neuroinflammation. Experimental autoimmune encephalitis (EAE) is a model of the disease. MS is classically treated with interferon beta (IFN-β) and glatiramer acetate (GA). Melatonin (MLT) has been reported to modulate immune system responses. The aim of the present study is to analyse the effects of MLT administration in comparison with the first-line treatments for MS (IFN-β and GA)...
March 8, 2018: Neurología: Publicación Oficial de la Sociedad Española de Neurología
https://www.readbyqxmd.com/read/29526118/first-line-disease-modifying-drugs-in-relapsing-remitting-multiple-sclerosis-an-italian-real-life-multicenter-study-on-persistence
#16
Diana Ferraro, Valentina Camera, Eleonora Baldi, Veria Vacchiano, Erica Curti, Angelica Guareschi, Susanna Malagù, Sara Montepietra, Silvia Strumia, Mario Santangelo, Luisa Caniatti, Matteo Foschi, Alessandra Lugaresi, Franco Granella, Ilaria Pesci, Luisa Motti, Walter Neri, Paolo Immovilli, Enrico Montanari, Francesca Vitetta, Anna Maria Simone, Patrizia Sola
OBJECTIVE: The introduction of oral disease-modifying drugs (DMDs) in addition to the available, injectable, ones for Relapsing-Remitting Multiple Sclerosis (RRMS) could be expected to improve medication persistence due to a greater acceptability of the route of administration. Aim of the study was to compare the proportion of patients discontinuing injectable DMDs (interferon beta 1a/1b, pegylated interferon, glatiramer acetate) with those discontinuing oral DMDs (dimethylfumarate and teriflunomide) during an observation period of at least 12 months...
March 10, 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29525836/monitoring-and-management-of-autoimmunity-in-multiple-sclerosis-patients-treated-with-alemtuzumab-practical-recommendations
#17
REVIEW
Virginia Devonshire, Richard Phillips, Hilary Wass, Gerald Da Roza, Peter Senior
Alemtuzumab is a humanized anti-CD52 monoclonal antibody approved in more than 65 countries for the treatment of relapsing-remitting multiple sclerosis (RRMS). Compared with subcutaneous interferon-beta-1a, alemtuzumab significantly reduced clinical disease activity and the rate of brain volume loss, and improved disability outcomes in patients with active RRMS who were either treatment naive (CARE-MS I study) or who had an inadequate response (≥ 1 relapse after ≥ 6 months of treatment) to prior therapy (CARE-MS II study)...
March 10, 2018: Journal of Neurology
https://www.readbyqxmd.com/read/29521573/effect-of-hla-drb1-alleles-and-genetic-variants-on-the-development-of-neutralizing-antibodies-to-interferon-beta-in-the-beyond-and-benefit-trials
#18
Dorothea Buck, Till Fm Andlauer, Wilmar Igl, Eva-Maria Wicklein, Mark Mühlau, Frank Weber, Karl Köchert, Christoph Pohl, Barry Arnason, Giancarlo Comi, Stuart Cook, Massimo Filippi, Hans-Peter Hartung, Douglas Jeffery, Ludwig Kappos, Frederik Barkhof, Gilles Edan, Mark S Freedman, Xavier Montalbán, Bertram Müller-Myhsok, Bernhard Hemmer
BACKGROUND: Treatment of multiple sclerosis (MS) with interferon β can lead to the development of antibodies directed against interferon β that interfere with treatment efficacy. Several observational studies have proposed different HLA alleles and genetic variants associated with the development of antibodies against interferon β. OBJECTIVE: To validate the proposed genetic markers and to identify new markers. METHODS: Associations of genetic candidate markers with antibody presence and development were examined in a post hoc analysis in 941 patients treated with interferon β-1b in the Betaferon® Efficacy Yielding Outcomes of a New Dose (BEYOND) and BEtaseron® /BEtaferon® in Newly Emerging multiple sclerosis For Initial Treatment (BENEFIT) prospective phase III trials...
March 1, 2018: Multiple Sclerosis: Clinical and Laboratory Research
https://www.readbyqxmd.com/read/29504299/neutralizing-antibodies-against-interferon-beta-in-korean-patients-with-multiple-sclerosis
#19
Jae Won Hyun, Gayoung Kim, Yeseul Kim, Byungsoo Kong, AeRan Joung, Na Young Park, Hyunmin Jang, Hyun June Shin, Su Hyun Kim, Suk Won Ahn, Ha Young Shin, So Young Huh, Woojun Kim, Min Su Park, Byung Jo Kim, Byoung Joon Kim, Jeeyoung Oh, Ho Jin Kim
BACKGROUND AND PURPOSE: Patients treated with interferon-beta (IFN-β) can develop neutralizing antibodies (NAbs) against IFN-β that can negatively affect the therapeutic response. This study assessed the prevalence of NAbs and the impact of NAb positivity on the therapeutic response to IFN-β in Korean patients with multiple sclerosis (MS). METHODS: This was a multicenter study involving 150 MS patients from 9 Korean medical centers who were treated with IFN-β for at least 6 months...
February 28, 2018: Journal of Clinical Neurology
https://www.readbyqxmd.com/read/29497558/risk-factors-for-fingolimod-induced-lymphopenia-in-multiple-sclerosis
#20
Ryohei Ohtani, Masahiro Mori, Tomohiko Uchida, Akiyuki Uzawa, Hiroki Masuda, Jia Liu, Satoshi Kuwabara
Background: Lymphopenia is a well-known adverse event of fingolimod, a disease-modifying drug for multiple sclerosis (MS). Objectives: The objective of this paper is to investigate risk factors for predicting fingolimod-induced lymphopenia in MS by frequent hematological monitoring. Methods: We retrospectively reviewed data of fingolimod-treated MS patients. Data assessed were sex, age, disease duration, medication history, body mass index, all attacks, Kurtzke's Expanded Disability Status Scale score, and absolute lymphocyte count (ALC) within two days before initiating fingolimod (baseline), on the day after first administration (day 2), and at least every other month after initiating fingolimod therapy...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
keyword
keyword
34053
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"